This new white paper discusses the rise of specialty medicines and the challenges presented for the industry in terms of demand, access and supply. It highlights the benefits of managed access programmes (MAPs) and their ability to provide access to treatments in countries where commercialisation may not be viable or where a formal licence has yet to be issued.
This shift from blockbuster to niche has operated in parallel with the rise of the empowered patient, and increasingly, fund-raising patient advocates, adding further complexity to the landscape.
The paper also outlines the approach needed to distribute specialty medicines and the challenges of operating within Europe, including the impact of a post-Brexit European Union.
To learn more about CHAPPER Healthcare, visit the website.